联苯双酯滴丸对肝纤维化指标与病理组织的影响

Effect of Bifendate Dripping Bills on Liver Fibrosis Markers in Blood Serum and Liver Histopathology

目的评价联苯双酯滴丸对肝纤维化指标,透明质酸(HA),层粘连蛋白(LN),Ⅳ型胶原(Ⅳ-C),Ⅲ型前胶原(PCⅢ)水平与病理组织变化的影响。方法178例病毒性肝炎(乙型),慢性(中度)患者随机分成治疗组和对照组,用放射免疫法测定治疗组与对照组患者治疗前、后的血清HA、LN、Ⅳ-C、PCⅢ水平;肝活检取肝组织检查,观察两组患者治疗前、后炎症和纤维化程度变化。结果治疗组在治疗前、后血清HA、LN、Ⅳ-C、PCⅢ水平变化有显著性差异(P<0.05),病理组织结果显示炎症程度有显著改善,而纤维化程度无显著变化。对照组在治疗前、后肝纤维化指标和病理组织无显著变化。结论联苯双酯滴丸治疗病毒性肝炎(乙型),慢性(中度)患者可显著改善肝纤维化四项指标,而对病理组织中纤维化程度无显著改善。

OBJECTIVE To evaluate the effect of bifendate dripping pills on liver fibrosis markers in blood serum, such as Hyalurnic Acid（HA）, laminin（LN）, type-Ⅳ collagen protein（Ⅳ-CP）, type-Ⅲ procollagen（PCⅢ）, and liver histopathological changes. METHODS 178 patients with chronic moderate viral hepatitis B divides into the treatment group and the control group randomly. The levels of these liver fibrosis markers in blood serum were detected by radioimmunoassay before and after therapy. Liver biopsy was taken to detect the inflammation and fibrosis degree change. RESULTS Bifendate dripping pills can significantly decrease the level of liver fibrosis markers in blood serum. Bifendate dripping pills can significantly degrade the liver pathological inflammation grades, while no significant influence on the pathological fibrosis stages. CONCLUSION Bifendate dripping pills can improve the liver fibrosis markers in blood serum. But it cannot significantly improve the liver histopathological fibrosis.